%0 Journal Article
%T Comparative theranostic efficacy of 177Lu- and 161Tb-labeled A1K2 SdAb in mesothelin-positive tumors
%W https://pubmed.ncbi.nlm.nih.gov/41454065/
%U https://doi.org/10.1007/s00259-025-07723-z
%X Mesothelin (MSLN), a 40 kDa glycoprotein normally confined to mesothelial cells, is overexpressed in several malignancies, including triple-negative breast cancer (TNBC). The anti-mesothelin single-domain antibody (sdAb, or “nanobody®”) DOTA-A1K2, previously validated for positron emission tomography (PET) imaging using site-specific 68Ga radiolabeling, may also serve as a radio-theranostic agent when labeled with 177Lu. Moreover, 161Tb has recently been proposed as an alternative to 177Lu that might provide additional efficacy due to the emission of Auger electrons. The aim of this study was to evaluate in vitro and in vivo the therapeutic effect of [177Lu]Lu-DOTA-A1K2 and [161Tb]Tb-DOTA-A1K2.
%G en
%J European Journal of Nuclear Medicine and Molecular Imaging
%A N’Guessan, Émilien
%A Raes, Florian
%A Ahmadi, Mitra
%A Bacot, Sandrine
%A Dumas, Laurent
%A Leenhardt, Julien
%A du Moulinet d’Hardemare, Amaury
%A Debiossat, Marlène
%A André, Clémence
%A Boutonnat, Jean
%A Durivault, Jérôme
%A Montemagno, Christopher
%A Lenormand, Jean-Luc
%A Djaïleb, Loïc
%A Köster, Ulli
%A Van de Voorde, Michiel
%A Ramaekers, Stijn
%A Verguts, Ken
%A Ghezzi, Catherine
%A Perret, Pascale
%A Lombardi, Charlotte
%A Broisat, Alexis
%D 2025-12-27
%K Lutetium-177
Mesothelin
Radio-ligand therapy
SdAb
Terbium-161
Triple negative breast cancer
user-project